Ranked #1 in 8 out of the 10 evaluated specialties by U.S. News
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Langerhans cell histiocytosis (LCH) is a rare disorder that occurs when your child has too many of a certain type of white blood cell.
Individualized care, new treatments
Through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, a 50-year partnership between Dana-Farber Cancer Institute and Boston Children's Hospital, patients with LCH receive individualized care to treat every aspect of this condition from an expert team of specialists. Patients also benefit from a team of researchers striving to understand the scientific causes of Langerhans cell histiocytosis, which results in continual introduction of new treatment options.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”